Orthotopic glioblastoma stem-like cell xenograft model in mice to evaluate intra-arterial delivery of bevacizumab: From bedside to bench

[1]  K. Camphausen,et al.  Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma , 2012, Journal of cellular and molecular medicine.

[2]  C. Hofstetter,et al.  Intra-Arterial Chemotherapy for Malignant Gliomas: A Critical Analysis , 2011, Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences.

[3]  M. Chopp,et al.  Effect of doublecortin on self‐renewal and differentiation in brain tumor stem cells , 2011, Cancer science.

[4]  J. Boockvar,et al.  Understanding the role of tumor stem cells in glioblastoma multiforme: a review article , 2011, Journal of Neuro-Oncology.

[5]  S. Brodie,et al.  Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. , 2011, Archives of ophthalmology.

[6]  T. Schwartz,et al.  Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article. , 2011, Journal of neurosurgery.

[7]  M. Souweidane,et al.  Optimization of glioblastoma multiforme stem cell isolation, transfection, and transduction , 2011, Journal of Neuro-Oncology.

[8]  Rong Wang,et al.  Glioblastoma stem-like cells give rise to tumour endothelium , 2010, Nature.

[9]  A. Falini,et al.  Cancer esearch cular and Cellular Pathobiology ermal Growth Factor Receptor Expression Identifies ctionally and Molecularly Distinct Tumor-Initiating Cells uman Glioblastoma Multiforme and Is Required R Gliomagenesis , 2010 .

[10]  A. Ciurea,et al.  Infiltrating growing pattern xenografts induced by glioblastoma and anaplastic astrocytoma derived tumor stem cells. , 2010, Chirurgia.

[11]  C. Eberhart,et al.  Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. , 2010, The American journal of pathology.

[12]  V. Tse,et al.  Firefly Luciferase–Based Dynamic Bioluminescence Imaging: A Noninvasive Technique to Assess Tumor Angiogenesis , 2010, Neurosurgery.

[13]  M. Souweidane,et al.  Balloon-Assisted Superselective Intra-Arterial Cerebral Infusion of Bevacizumab for Malignant Brainstem Glioma , 2010, Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences.

[14]  J. Beijnen,et al.  High-grade glioma mouse models and their applicability for preclinical testing. , 2009, Cancer treatment reviews.

[15]  P. Keegan,et al.  FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. , 2009, The oncologist.

[16]  Susan Bell,et al.  Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Michael D. Prados,et al.  A human brainstem glioma xenograft model enabled for bioluminescence imaging , 2009, Journal of Neuro-Oncology.

[18]  Colin M. Wilson,et al.  Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors , 2009, Journal of Translational Medicine.

[19]  D. Ballon,et al.  Novel Microcatheters for Selective Intra-Arterial Injection of Fluid in the Rat Brain , 2009, American Journal of Neuroradiology.

[20]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[21]  P. Dirks,et al.  Brain tumor stem cells: bringing order to the chaos of brain cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  L. Abrey Bevacizumab in recurrent malignant glioma , 2008, Current neurology and neuroscience reports.

[23]  Kornelia Polyak,et al.  The cancer stem cell hypothesis: in search of definitions, markers, and relevance , 2008, Laboratory Investigation.

[24]  Darell D. Bigner,et al.  Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.

[25]  H. Newton Intra-arterial chemotherapy of primary brain tumors , 2005, Current treatment options in oncology.

[26]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[27]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[28]  R A Moats,et al.  Time course of bioluminescent signal in orthotopic and heterotopic brain tumors in nude mice. , 2003, BioTechniques.

[29]  C. Hofstetter,et al.  Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival. , 2012, World neurosurgery.

[30]  J. Knopman,et al.  Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma. , 2009, Journal of experimental therapeutics & oncology.

[31]  C. Altaner,et al.  Glioblastoma and stem cells. , 2008, Neoplasma.

[32]  I. Bayazitov,et al.  A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.